Year-over-year earnings per share growth for the last twelve months: Unity Biotechnology, Inc. (UBX)
Unity Biotechnology (UBX) focuses on ophthalmologic senolytics, which creates significant binary risks for capital. Meanwhile, the company adheres to strict ethical standards and minimizes laboratory waste. On GURU.Markets, the quarterly EPS trajectory confirms the current trend, where 0.00 records a new level. In the future, business returns will be based on the commercialization of drugs that eliminate the body's senescent cells.
Analytical breakdowns and data insights for company Unity Biotechnology, Inc (UBX)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- book capitalization data:
- company liabilities and liquidity data:
Total Debt to Capital Unity Biotechnology|UBX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Unity Biotechnology|UBX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Unity Bio|UBX - Company Long-Term Indebtedness|Company Short-Term Debt Unity Biotechnology|Quick Liquidity unitybiotechnology.com
- earnings and valuation multiples information:
UBX - Company Net Income|Expected Profit Unity Biotechnology|UBX - Market Cap to Earnings|Forward P/E Multiple Unity Bio|UBX - Price to Net Income Growth Ratio|Enterprise Value to EBITDA Ratio Unity Bio|UBX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Unity Biotechnology|UBX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth unitybiotechnology.com|UBX - Earnings per share growth in current year|Expected earnings per share growth for next year Unity Biotechnology
Summary company analytics:Unity Biotechnology
Unity Biotechnology's leadership in developing senolytic molecules requires colossal R&D expenditures, making the monitoring of net income critical for assessing investment efficiency. Tracking quarterly EPS growth allows for a real-time assessment of earnings per share dynamics relative to revenue, where an upward trend confirms the sustainability of the business model, while a local peak signals a risk of the asset being overbought.
Key competitors
TEM: Quarterly EPS earnings growth|QGEN - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Ionis Pharma|Earnings per share growth in annualized terms for the last twelve months Repligen Inc. RGEN|Year-over-year net earnings per share growth for the last 12 months RNA (Avidity Biosciences)|Year-over-year earnings per share growth rate for the last twelve months CRSP|Quarterly EPS earnings growth WGS (GeneDx)|Ultragenyx Pharmaceutical Inc. (RARE) - Earnings per share growth in annualized terms for the last twelve months|Beam Therapeutics Corp - Quarterly EPS earnings growth|Sarepta Corp (SRPT) - Year-over-year net earnings per share growth for the last 12 months|TWST: Quarterly EPS earnings growth|10xgenomics.com - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Intellia Therapeutics, Inc.|Year-over-year earnings per share growth for the last 12 months STOK (Stoke Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months BioLife Corp (BLFS)|WVE - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Maze Therapeutics Inc MAZE|sionnatx.com - Year-over-year earnings per share growth for the last twelve months|PRME - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Taysha Gene Therapies Inc|QURE: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year MeiraGTx Corp MGTX|Year-over-year net earnings per share growth for the last 12 months RGNX|Earnings per share growth in annualized terms for the last twelve months solidbio.com SLDB|Year-over-year net earnings per share growth for the last 12 months OCGN (Ocugen)|Quarterly EPS earnings growth Pacific Biosciences of California, Inc. (PACB)|Quarterly EPS earnings growth BNTC (Benitec)|Design Corp - Year-over-year earnings per share growth for the last twelve months|RCKT: Year-over-year net earnings per share growth for the last 12 months|FDMT (4dmoleculartherapeutics.com) - Year-over-year earnings per share growth for the last 12 months|LXEO: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months KRRO|Year-over-year earnings per share growth for the last twelve months Editas|Year-over-year earnings per share growth for the last 12 months SLN (Silence Therapeutics Corp)|Quarterly EPS earnings growth PRQR|Quarterly EPS earnings growth codexis.com (CDXS)|Sangamo Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Nautilus Biotechnology, Inc. NAUT|MGX - Year-over-year earnings per share growth for the last twelve months|DTIL (precisionbiosciences.com) - Year-over-year earnings per share growth for the last 12 months|GBIO: Quarterly EPS earnings growth|BOLD - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months XCUR|IMNN (Celsion Corporation) - Year-over-year earnings per share growth rate for the last twelve months|Year-over-year net earnings per share growth for the last 12 months PHIO (Phio Pharmaceuticals)|MBIO - Earnings per share growth in annualized terms for the last twelve months|TransCode Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BNGO|Applied DNA Sciences, Inc. - Quarterly EPS earnings growth|BLUE: Year-over-year earnings per share growth for the last twelve months|IPA: Quarterly EPS earnings growth|OMGA - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Singular Genomics Systems|Earnings per share growth in annualized terms for the last twelve months regulusrx.com RGLS|Year-over-year net earnings per share growth for the last 12 months SYRS (Syros Pharmaceuticals, Inc.)|Year-over-year earnings per share growth rate for the last twelve months TBIO|Quarterly EPS earnings growth TCON (TRACON)
